Today the administration released the details of its proposed FY 2026 budget request, including a nearly 40% reduction in funding for the National Institutes of Health (NIH) and the National Cancer ...

“This study shows that sacituzumab govitecan, when combined with pembrolizumab as an initial treatment for patients with metastatic triple-negative breast cancer, delivers superior disease control and ...

"This trial raises an intriguing hypothesis: that the increasingly popular GLP-1 medications used to treat diabetes and obesity might offer some benefit in reducing the risk of developing cancer. I ...

“Trastuzumab deruxtecan is approved for patients with metastatic HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma who received a prior trastuzumab-based regimen based on ...

"These early, interim results from a promising prospective, randomized study evaluating the role of adjuvant chemotherapy in patients with stage IA-IIA non-small cell lung cancer identified as ...

The Association for Clinical Oncology (ASCO) is urging the House and Senate Subcommittees on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies to support cancer ...

The Food and Drug Administration (FDA) is announcing the establishment of a docket to solicit public comment for information on dihydropyrimidine dehydrogenase (DPD) deficiency and the use of ...

Luis E. Raez, Xylina T. Gregg, Gurjyot K. Doshi, Scott Freeswick, Austin Cox, Neal Dave, Kashyap B. Patel, Melissa S. Dillmon, Stuart Genschaw, Elizabeth V ...

The ASCO-Sponsored Patient Advocacy Booth at the ASCO Annual Meeting provides complimentary exhibit space where not-for-profit patient advocacy organizations may promote their programs, services, and ...

Formerly the JCO Journals Lounge, JCO Central is a place of community for oncology authors, researchers, or anyone interested in publishing. Meet with JCO Journals editors and discuss manuscript ...

An internationally recognized oncology leader and health care executive, Dr. Knudsen is the CEO of the Parker Institute for Cancer Immunotherapy. Dr. Knudsen was previously CEO of the American Cancer ...